U.S. markets closed
  • S&P Futures

    3,830.75
    +2.75 (+0.07%)
     
  • Dow Futures

    31,379.00
    +8.00 (+0.03%)
     
  • Nasdaq Futures

    12,793.50
    -38.25 (-0.30%)
     
  • Russell 2000 Futures

    2,191.00
    -9.00 (-0.41%)
     
  • Crude Oil

    62.96
    -0.57 (-0.90%)
     
  • Gold

    1,767.00
    -8.40 (-0.47%)
     
  • Silver

    27.29
    -0.39 (-1.43%)
     
  • EUR/USD

    1.2157
    -0.0030 (-0.24%)
     
  • 10-Yr Bond

    1.5180
    +0.1290 (+9.29%)
     
  • Vix

    28.89
    +7.55 (+35.38%)
     
  • GBP/USD

    1.3986
    -0.0027 (-0.19%)
     
  • USD/JPY

    106.2750
    +0.0450 (+0.04%)
     
  • BTC-USD

    47,069.43
    -2,878.80 (-5.76%)
     
  • CMC Crypto 200

    938.79
    -55.88 (-5.62%)
     
  • FTSE 100

    6,651.96
    -7.01 (-0.11%)
     
  • Nikkei 225

    29,535.87
    -632.40 (-2.10%)
     

Radius Health to Present at 9th Annual SVB Leerink Partners Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

WALTHAM, Mass., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (RDUS), today announced that Jesper Høiland, President & CEO and Pepe Carmona, CFO will present a corporate update at the 9th Annual SVB Leerink Partners Global Healthcare Conference at 10:30 a.m. ET on Thursday, February 27, 2020.

A live webcast of the presentation will be available by visiting the Investors’ section of the Company’s website at https://ir.radiuspharm.com/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Radius

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Radius’ lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes an investigational abaloparatide-patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in hormone-receptor positive breast cancer. For more information, please visit www.radiuspharm.com.

Investor Relations Contact:

Elhan Webb, CFA
Email: ewebb@radiuspharm.com
Phone: 617-551-4011